

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA MEDICAL SYSTEM HOLDINGS LIMITED

康哲藥業控股有限公司*

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 867)

Voluntary and Business Update Announcement

Methylthioninium Chloride Enteric-coated Sustained-release Tablets

Granted an Approval for Drug Clinical Trial

China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the innovative patented drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets (the “Product”), which was licensed in by the Group on 3 December 2020 from Cosmo Technologies Ltd., has been granted an approval for drug clinical trial issued on 2 August 2021 by the National Medical Products Administration of the People’s Republic of China and agreed to carry out a randomized, double-blind, placebo controlled, multi-centre clinical trial of the efficacy and safety of the Product in patients undergoing colorectal cancer screening or surveillance colonoscopy.

The Product is an oral diagnostic drug, being designed to increase the detection sensitivity of colorectal cancer/precancerous lesions (such as adenomas) by enhancing visualization of the colorectal lesions in adult patients undergoing screening or surveillance colonoscopy. The Product has been approved by the European Medicines Agency (EMA) to be commercialized in Europe under the trade name Lumeblue™ in August 2020.

The Group is currently actively preparing for initiating the clinical trial of the Product.

The announcement is made on a voluntary basis by the Company. Shareholders and investors are advised to exercise caution when dealing in the shares and other securities of the Company.

By order of the Board
China Medical System Holdings Limited
Lam Kong
Chairman

Hong Kong, 2 August 2021

As at the date of the announcement, the directors of the Company comprise (i) Mr. Lam Kong, Mr. Chen Hongbing and Ms. Chen Yanling as executive Directors; and (ii) Mr. Wu Chi Keung, Mr. Leung Chong Shun and Ms. Luo, Laura Ying as independent non-executive Directors.